Autoinflation reduces middle ear effusion in children with otitis media with effusion

10.1136/ebmed-2015-110330

Armin Bidarian-Moniri1,2,3
1Department of Otorhinolaryngology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden; 2Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal; 3Department of Clinical Sciences, S Gonçalo Academy, Hospital S Gonçalo, Lagos, Portugal

Correspondence to: Dr Armin Bidarian-Moniri, Department of Otorhinolaryngology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Öron- näs- och halssjukvård, Område 5, Gröna stråket 5-9, Göteborg 413 45, Sweden; armin.bidarian@vgregion.se

Commentary on: Williamson I, Vennik J, Harnden A, et al. Effect of nasal balloon autoinflation in children with otitis media with effusion in primary care: an open randomized controlled trial. CMAJ 2015;187:961–9.

Context
Otitis media with effusion (OME) is defined as accumulation of fluid in the middle ear in absence of signs or symptoms of an acute ear infection. OME is usually associated with a conductive hearing loss that may affect the quality of life. Surgical treatment of OME with grommets is associated with substantial healthcare costs and is usually considered after a period of watchful waiting, leaving most children with OME untreated during this period. This raises the need for an efficient, non-invasive treatment option that can be offered to children with OME at an early stage.

In 1968, Hunt-Williams presented a new method for autoinflation involving a plastic end-piece connected to a balloon, later developed into the Otovent device. The present study evaluates the effect of autoinflation with this method on children with OME.

Methods
This was a randomised controlled trial (RCT) set in 43 family practices in the UK including 320 children aged 4–11 years with otitis media with effusion in one or both ears, confirmed by tympanometry. The plastic end-piece in the Otovent device was adapted to a nostril and, while the other nostril was occluded, the children were instructed to inflate the balloon. The children were allocated to either autoinflation three times daily for 1–3 months in addition to usual care (intervention) or usual care alone (control). Clearance of middle-ear fluid at 1 and 3 months was evaluated by tympanometry. Ear-related quality of life was assessed at 3 months using the OMQ-14 (an ear-related measure of quality of life). The results are reported as relative risk (RR) or OR estimates and CIs. The methodology is adhered to recognised international protocols for RCTs.

Findings
Children performing autoinflation were more likely to achieve a normal tympanogram at 1 month compared to controls (47.3% (62/131) vs 35.6% (47/132); adjusted relative risk (RR) 1.36, 95% CI 0.99 to 1.88) and at 3 months (49.6% (62/125) vs 38.3% (46/120); adjusted RR 1.37, 95% CI 1.03 to 1.89). The improvement in ear-related quality of life, as judged by OMQ-14, was superior in the autoinflation group compared to the control group (score −0.42, 95% CI −0.63 to −0.22). Compliance was 89% at 1 month and 80% at 3 months. There was no significant difference in adverse events between the groups.

Commentary
This RTC evaluated the effect of autoinflation with the Otovent device on children with OME, and achieved some positive results. However, only children aged 4–11 years were included, while OME culminates between the ages of 1–4 years with decreasing prevalence thereafter. Additionally, the primary indication for treatment of OME is the restoration of normal hearing, yet hearing testing was not performed in this study. The follow-up period was also limited to 3 months, making it impossible to evaluate the long-term outcome of this treatment.

The most recent Cochrane review gave a relatively weak recommendation regarding autoinflation in treatment for children with OME based on the short follow-up time and the lack of adequate hearing evaluation in previous studies. An efficient treatment for OME should be appropriate for children younger than 4 years of age and the study protocol should include hearing testing and a long-term follow-up.

This study shows that autoinflation reduces middle ear effusion and improves the quality of life in children with OME.

The large sample size from family practices may permit generalisation of the results to a normal population. The simplicity of the Otovent device allows for early intervention during the watchful waiting period. Future studies should assess the effect on hearing and the long-term outcome.

Implications for practice
This study provides evidence that autoinflation may reduce middle ear effusion and the related symptoms in some children with OME. Given its low cost and non-invasive character, it may be reasonable to apply this method to improve symptoms and hopefully avoid surgery in children with OME.

Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.

References
1. Hellström S, Persson A. [Tympanostomy tube treatment in otitis media. A systematic literature review. SBU summary and conclusions]. Lakartidningen 2008;105:2104–6.
2. Hunt-Williams R. A method for maintaining middle-ear ventilation in children. J Laryngol Otol 1968;82:921–6.
3. Paradise JL, Rockette HE, Colborn DK, et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997;99:318–33.
4. Perera R, Glasziou PP, Heneghan CJ, et al. Autoinflation for hearing loss associated with otitis media with effusion. Cochrane Database Syst Rev 2013;5:CD006285.
5. Bidarian-Moniri A, Ramos MJ, Ejnell H. Autoinflation for treatment of persistent otitis media with effusion in children: a cross-over study with a 12-month follow-up. Int J Pediatr Otorhinolaryngol 2014;78:1298–305.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/